Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-05-10
2005-05-10
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S221000, C514S228500, C514S233200, C514S243000, C540S469000, C540S575000, C544S112000, C544S184000
Reexamination Certificate
active
06890922
ABSTRACT:
The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
REFERENCES:
patent: 2705715 (1955-04-01), Baker et al.
patent: 3036070 (1962-05-01), Druey et al.
patent: 3169129 (1965-02-01), Rodgers et al.
patent: 3331840 (1967-07-01), Fry et al.
patent: 3333961 (1967-08-01), Fry et al.
patent: RE26565 (1969-04-01), Rodgers et al.
patent: 3840537 (1974-10-01), Garside et al.
patent: 3941785 (1976-03-01), Clarke et al.
patent: 4039544 (1977-08-01), Broughton et al.
patent: 4052390 (1977-10-01), Broughton et al.
patent: 4060615 (1977-11-01), Matier et al.
patent: 4159330 (1979-06-01), Doria et al.
patent: 4167568 (1979-09-01), Knowles et al.
patent: 4278673 (1981-07-01), Hartley et al.
patent: 4379788 (1983-04-01), Heider et al.
patent: 4431440 (1984-02-01), Bhalla et al.
patent: 4666908 (1987-05-01), Hamilton
patent: 4885301 (1989-12-01), Coates
patent: 4923874 (1990-05-01), McMahon et al.
patent: 5047404 (1991-09-01), Coates et al.
patent: 5073559 (1991-12-01), Coates
patent: 5075310 (1991-12-01), Coates et al.
patent: 5147875 (1992-09-01), Coates et al.
patent: 5250534 (1993-10-01), Bell et al.
patent: 5254571 (1993-10-01), Coates et al.
patent: 5272147 (1993-12-01), Bell et al.
patent: 5294612 (1994-03-01), Bacon et al.
patent: 5316906 (1994-05-01), Haugland et al.
patent: 5346901 (1994-09-01), Bell et al.
patent: 5426107 (1995-06-01), Bell et al.
patent: 5482941 (1996-01-01), Terrett
patent: 5591742 (1997-01-01), Bell et al.
patent: 5719283 (1998-02-01), Bell et al.
patent: 5734053 (1998-03-01), Terrett
patent: 6100270 (2000-08-01), Campbell
patent: 865125 (1978-09-01), None
patent: 2255172 (1973-05-01), None
patent: 2811780 (1978-09-01), None
patent: 2364076 (1994-07-01), None
patent: 0009384 (1980-04-01), None
patent: 0162715 (1985-11-01), None
patent: 0201188 (1986-12-01), None
patent: 0293063 (1988-11-01), None
patent: 0347146 (1989-12-01), None
patent: 0349239 (1990-01-01), None
patent: 0351058 (1990-01-01), None
patent: 0371731 (1990-06-01), None
patent: 0352960 (1990-09-01), None
patent: 0442204 (1991-08-01), None
patent: 0463756 (1992-01-01), None
patent: 0526004 (1993-02-01), None
patent: 0636626 (1995-02-01), None
patent: 0669324 (1995-08-01), None
patent: 0702555 (1996-03-01), None
patent: 0812845 (1997-12-01), None
patent: 1338235 (1973-11-01), None
patent: 9306104 (1993-04-01), None
patent: 9307149 (1993-04-01), None
patent: 9312095 (1993-06-01), None
patent: 9400453 (1994-01-01), None
patent: 9405661 (1994-03-01), None
patent: 9428902 (1994-12-01), None
patent: 9429277 (1994-12-01), None
patent: 9616657 (1996-06-01), None
patent: 9703675 (1997-02-01), None
Ahn, H.S., Crim, W., Pitts, B., and Sybertz, E.J., “Calcium-Calmodulin-Stimulated and Cyclic-GMP-Specific Phosphodiesterases”, Advances in Second Messenger and Phosphoprotein Research, 25: 271-283 (1992).
Aronson, W. J., Trigo-Rocha, F., Ignarro, L. J., and Rajfer, J., “The Role of Nitric Oxide and Cyclic GMP in Mediating Pelvic Nerve Stimulation Induced Erection in Dogs”, J. Urology, 147: 454A (1992).
Azadzoi, K. M., and Saenz de Tejada, I., “Diabetes Mellitus Impairs Neurogenic and Endothelium-Dependent Relaxation of Rabbit Corpus Cavernosum Smooth Muscle”, J. Urol., 148: 1587-1591 (Nov. 1992).
Azadzoi, K. M., Kim, N., Brown, M. L., Goldstein, I., Cohen, R. A., and Saenz de Tejada, I., “Endothelium-Derived Nitric Oxide and Cyclooxygenase Products Modulate Corpus Cavernosum Smooth Muscle Tone”, J. Urol., 147: 220-225 (Jan. 1992).
Azadzoi, K. M., and Saenz de Tejada, I., “Hypercholesterolemia Impairs Endothelium-Dependent Relaxation of Rabbit Corpus Cavernosum Smooth Muscle”, J. Urol. 146: 238-240 (Jul. 1991).
Beavo, J. A., “Cyclic Nucleotide Phosphodiesterases: Functional Implications of Multiple Isoforms”, Physiological Reviews, 75(4): 725-748 (Oct. 1995).
Beavo, J. A., Conti, M., and Heaslip, R. J., “Multiple Cyclic Nucleotide Phosphodiesterase”, Mol. Pharmacol., 46: 399-405 (1994).
Beavo, J. A., and Reifsnyder, D. H., “Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors”, TIPS, 11: 150-155 (Apr. 1990).
Bowman, A., and Drummond, A. H., “Cyclic GMP mediates neurogenic relaxation in the bovine retractor penis muscle”, Br. J. Pharmac., 81: 665-674 (1984).
Burger, A., Med. Chem., 2nded., Interscience Publishers, Inc., New York (1960), “Relaxation of Chemical Structure and Biological Activity”, pp. 36-45.
Bush, M. A., PhD Thesis, University of California, Los Angeles (1993), “The Role of the L-Arginine-Nitric Oxide-Cyclic GMP Pathway in Relaxation of Corpus Cavernosum Smooth Muscle”.
Bush, P. A., Gonzalez, N. E., and Ignarro, L. J., “Biosynthesis of Nitric Oxide and Citrulline from L-Arginine by Constitutive Nitric Oxide Synthase Present in Rabbit Corpus Cavernosum”, Biochem. & Biophys. Res. Comm., 186(1): 308-314 (Jul. 1992).
Bush, P. A., Aronson, W. J., Rajfer, J., Buga, G. M., and Ignarro, L. J., “Comparison of nonadrenergic, noncholingergic- and nitric oxide-mediated relaxation of corpus cavernosum”, Int. J. Impotence Res., 4: 85-93 (1992).
Bush, P. A., Aronson, W. J., Buga, G. M., Rajfer, J., and Ignarro, L. J., “Nitric Oxide is a Potent Relaxant of Human and Rabbit Corpus Cavernosum”, J. Urology, 147: 1650-1655 (Jun. 1992).
Coste, H., and Grondin, P., “Characterization of a Novel Potent and Specific Inhibitor of Type V Phosphodiesterase”, Biochemical Pharmacology, 50(10): 1577-1585 (1995).
Dumaitre, B., and Dodie, N., “Synthesis and Cyclic GMP Phosphodiesterase Inhibitory Activity of a Series of 6-Phenylpyrazolo[3,4-d]pyrimidones”, J. Med. Chem., 39: 1635-1644 (1996).
Goodman and Gilman's,The Pharmacological Basis of Therapeutics,Ed. Gilman, et al., McGraw Hill, 8thed., (1990), pp. 33-43.
Hamilton, H. W., Ortwine, D. F., Worth, D. F., and Bristol, J. A., “Synthesis and Structure—Activity Relationships of Pyrazolo[4,3-d]pyrimidin-7-ones as Adenosine Receptor Antagonists”, J. Med. Chem., 30:91-96 (1987).
Holmquist, F., Fridstrand, M., Hedlund, H., and Anderson, K. E., “Actions of 3-Morpholinosydnonimin (SIN-1) on Rabbit Isolated Penile Erectile Tissue”, J. Urology, 150:1310-1315 (Oct. 1993).
Holmquist, F., Stief, C. G., Jonas, U., and Anderson, K.-F., “Effects of the Nitric Oxide Synthase Inhibitor NG-Nitro-L-Arginine on the Erectile Response to Cavernosum Nerve Stimulation in the Rabbit”, Acta Physiol. Scand., 143: 299-304 (1991).
Ignarro, L. J., et al., “Neurotransmitter Identity Doubt”, Nature, 347: 131 (Sep. 1990).
Ignarro, L. J., Bush, P. A., Buga, G. M., Wood, K. S., Fukuto, J. M., and Rafjer, J., “Nitric Oxide and Cyclic GMP Formation Upon Electrical Field Stimulation Cause Relaxation of Corpus Cavernosum Smooth Muscle”, Biochem. & Biophys. Res. Comm., 170(2): 843-850 (Jul. 1990).
Kim, N., Vardi, Y., Padma-Nathan, H., Daley, J., Goldstein, I., and Saenz de Tejada, I., “Oxide Tension Regulates the Nitric Oxide Pathway. Physiological Role in Penile Erection”, J. Clin. Invest., 91:437-442 (Feb. 1993).
Kim, N., Azadzoi, K. M., Goldstein, I., and Saenz de Tejada, I., “A Nitric Oxide-like Factor Mediates Nonadrenergic-Noncholinergic Neurogenic Relaxation of Penile Corpus Cavernosum Smooth Muscle”, J. Clin. Inv., 88: 112-118 (July 1991).
Korenman, S. G., and Viosca, S. P., “Treatment of Vasculogenic Sexual Dysfunction with Pentoxifylline”, JAGS, 41(4): 363-366
Bischoff Erwin
Dembowsky Klaus
Es-Sayed Mazen
Haning Helmut
Keldenich Jörg
Bayer Healthcare AG
Kifle Bruck
Pellegrino Susan M.
LandOfFree
2-phenyl substituted imidazotriazinones as phosphodiesterase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-phenyl substituted imidazotriazinones as phosphodiesterase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-phenyl substituted imidazotriazinones as phosphodiesterase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3398253